Table 2.
Author, ref | No. of pts | TNM staging | Sensitivity | Specificity | Accuracy |
---|---|---|---|---|---|
Bailey et al. [18] | 22 | – | – | – | – |
Brendle et al. [19] | 15 | Non-mucinous s/rTNM | 68% | 88% | 76% |
Mucinous s/rTNM | 38% | 85% | 52% | ||
Crimì et al. [20] | 36 | T (after pCRT) | 100% | 73% | 92% |
N (after pCRT) | 90% | 92% | 92% | ||
Jeong et al. [16] | 9 | – | – | – | – |
Kang et al. [21] | 51 | sT | – | – | 100% |
sN | – | – | 42% | ||
Lee et al. [22] | 59 | sT | – | – | 93% |
sN | 93% | – | – | ||
sM (liver) | 100% | – | – | ||
rM (liver) | 75% | – | – | ||
Paspulati et al. [23] | 12 | rN and rM | 86% | 100% | 95% |
Plodeck et al. [24] | 44 | rTNM | 94% | 94% | 94% |
Rutegård et al. [25] | 24 | – | – | – | – |
Yoon et al. [26] | 71 | sM | 94% | 98% | – |
T tumor, N nodal, M metastases, s staging before or after preoperative chemoradiotherapy, r restaging after surgery or suspect of recurrent disease, pCRT preoperative chemoradiation therapy